CARM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CARM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. CARISMA Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -721.36%.
The historical rank and industry rank for CARISMA Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:
During the past 4 years, CARISMA Therapeutics's highest ROC (Joel Greenblatt) % was -547.10%. The lowest was -805.69%. And the median was -679.86%.
CARISMA Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The historical data trend for CARISMA Therapeutics's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARISMA Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
ROC (Joel Greenblatt) % | -547.10 | -751.96 | -607.76 | -792.70 |
CARISMA Therapeutics Quarterly Data | ||||||||||||
Dec20 | Jun21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
ROC (Joel Greenblatt) % | Get a 7-Day Free Trial | -733.64 | -754.24 | -908.29 | -998.89 | -721.36 |
For the Biotechnology subindustry, CARISMA Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where CARISMA Therapeutics's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
ROC (Joel Greenblatt) % | = | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) |
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Working Capital | (Q: Dec. 2023 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (0 | + | 0 | + | 2.866) | - | (8.495 | + | 1.413 | + | 4.065) |
= | -11.107 |
Working Capital | (Q: Mar. 2024 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (0 | + | 0 | + | 4.438) | - | (6.014 | + | 1.189 | + | 2.074) |
= | -4.839 |
When net working capital is negative, 0 is used.
So ROC (Joel Greenblatt) % of CARISMA Therapeutics for the quarter that ended in Mar. 2024 can be restated as:
ROC (Joel Greenblatt) % | (Q: Mar. 2024 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Dec. 2023 | Q: Mar. 2024 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | -78.04 | / | ( ( (8.937 + max(-11.107, 0)) | + | (12.7 + max(-4.839, 0)) ) | / | 2 ) |
= | -78.04 | / | ( ( 8.937 | + | 12.7 ) | / | 2 ) |
= | -78.04 | / | 10.8185 | ||||
= | -721.36 % |
Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARISMA Therapeutics (NAS:CARM) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.
Thank you for viewing the detailed overview of CARISMA Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Modernatx, Inc. | 10 percent owner | 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Sanford S Zweifach | director | 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021 |
Steven Kelly | director, officer: President and CEO | C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Briggs Morrison | director | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451 |
Richard Steven Morris | officer: Chief Financial Officer | 397 EAGLEVIEW BOULEVARD, EXTON PA 19341 |
Chidozie Ugwumba | director | 158 FILMORE STREET, DENVER CO 80206 |
Michael Klichinsky | officer: Chief Scientific Officer | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Michael Torok | director | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Regina Hodits | director | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Bjorn Odlander | director | C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51 |
Minori Rosales | officer: Chief Development Officer | 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Jewett Michael A. S. | director | C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Peter Honig | director | 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
Patricia M. Drake | officer: Chief Commercial Officer | 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Elly Ryu | officer: Principal Accounting Officer | 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
From GuruFocus
By PRNewswire • 10-25-2023
By PRNewswire • 12-14-2023
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 05-08-2023
By PRNewswire PRNewswire • 05-05-2023
By PRNewswire • 06-28-2023
By PRNewswire • 09-05-2023
By PRNewswire • 11-28-2023
By PRNewswire PRNewswire • 05-30-2023
By PRNewswire • 08-24-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.